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Abstract
Prostate cancer is a major health problem for men in Western societies. Here we report a Prostate Cancer-Specific Targeting
Gene-Viro-Therapy (CTGVT-PCa), in which PTEN was inserted into a DD3-controlled oncolytic viral vector (OV) to form
Ad.DD3.E1A.E1B(D55)-(PTEN) or, briefly, Ad.DD3.D55-PTEN. The woodchuck post-transcriptional element (WPRE) was also
introduced at the downstream of the E1A coding sequence, resulting in much higher expression of the E1A gene. DD3 is
one of the most prostate cancer-specific genes and has been used as a clinical bio-diagnostic marker. PTEN is frequently
inactivated in primary prostate cancers, which is crucial for prostate cancer progression. Therefore, the Ad.DD3.D55-PTEN
has prostate cancer specific and potent antitumor effect. The tumor growth rate was almost completely inhibited with the
final tumor volume after Ad.DD3.D55-PTEN treatment less than the initial volume at the beginning of Ad.DD3.D55-PTEN
treatment, which shows the powerful antitumor effect of Ad.DD3.D55-PTEN on prostate cancer tumor growth. The CTGVT-
PCa construct reported here killed all of the prostate cancer cell lines tested, such as DU145, 22RV1 and CL1, but had a
reduced or no killing effect on all the non-prostate cancer cell lines tested. The mechanism of action of Ad.DD3.D55-PTEN
was due to the induction of apoptosis, as detected by TUNEL assays and flow cytometry. The apoptosis was mediated by
mitochondria-dependent and -independent pathways, as determined by caspase assays and mitochondrial membrane
potential.
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Introduction
Prostate cancer is a major health problem for men in Western
societies. Each year, approximately 230,000 American males are
diagnosed with prostate cancer and nearly 30,000 die from this
disease [1,2]. The best available treatment for patients with the
advanced disease is androgen ablation therapy, based on the
observations of Huggins and Hodges [3] that clinical prostate
cancer is under the trophic influence of male hormones. Tumor
regression and improvement of clinical symptoms are temporary
and the disease inevitably progresses to an androgen-independent
state. Currently, no curative therapy is available for androgen-
independent prostate cancers.
Bio-therapy provides an attractive opportunity to target
androgen-independent prostate cancers. Unlike traditional che-
motherapy, it can be designed and customized to specifically target
cancers according to our understanding of the disease at a
molecular level. The adenoviral vector has been used as a transfer
vehicle to introduce genes into cancer cells because it is more
efficient than non-viral gene transfer methods [4,5]. The
adenoviral vector is stable in vivo, efficiently delivers genes to both
dividing and non-dividing cells and rarely causes any significant
disease itself [6,7]. However, the traditional adenovirus used for
gene therapy is a replication deficient one with low expression level
of the therapeutic gene. Cancer-specific replication of the
oncolytic vector, therefore, is absolutely required to prevent these
problems. Two major strategies have been used to construct a
replicative and cancer-specific oncolytic adenovirus. The first is to
delete the viral element that is necessary for virus replication in
normal cells, which is not required in tumor cells. For example, the
E1B-55K gene, which was deleted in the oncolytic viruses ONYX-
015 and ZD55 [8,9,10], is required for viral replication in normal
cells but is dispensable in cancer cells due to compensatory
mechanisms. The second strategy is to replace the promoter of a
key gene in adenovirus replication, such as the E1A or E1B gene,
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is highly replicated when the promoter is activated.
To overcome the limitations of traditional gene therapy with an
replication deficient adenoviral vector, a Cancer-Targeting Gene-
Viro-Therapy (CTGVT) was constructed by inserting an anti-
tumor gene into a double-targeted oncolytic viral(OV) vector. It is
actually an OV-gene, and has much better antitumor effect than
that of either gene therapy alone or virotherapy alone. The
oncolytic virus itself has anti-tumor power and selectively
replicates several hundred-fold in tumor cells and thus, the
therapeutic genes should also be selectively replicated several
hundred-fold in tumor cells [11]. By innovatively integrating gene
therapy and viro-therapy, the anti-tumor effect of the CTGVT is
generally much higher than either method alone. On January 27,
2011, Amgen spent 1 billion USD to purchase OncoHSV-GM-
CSF (an oncolytic virus from Herpes Simplex Virus-1), which is in
phase III for advanced melanoma [13,14], underlining the
importance and potential of the CTGVT strategy.
In this study, we first generated a double-regulated adenovirus,
Ad.DD3.D55, in which the E1A gene is under the control of DD3
promoter and the E1B-55K gene was deleted. DD3 is one of the
most prostate cancer-specific genes and has been used as a clinical
biomarker for prostate cancer [15]. Interestingly, a 214-bp
fragment of the DD3 core promoter has a high promoter activity
[16], and therefore it was used to control E1A expression in the
oncolytic adenovirus. Because DD3 expression is highly restricted
in prostate cancer, we previously used the minimal DD3 promoter
to drive expression of E1A for generating an oncolytic virus [17].
The level of DD3 promoter-driven E1A expression was insuffi-
cient, therefore, WPRE was introduced to enhance the expression
of the E1A gene in this study. WPRE promotes gene expression in
a promoter- and cell-line-dependent manner [18]. WPRE has
been exploited as an enhancer of transgene expression by
enhancing nuclear export of an aberrantly retained messenger
RNA from the nucleus to the cytoplasm [19]. In addition, PTEN is
a well-known tumor suppressor gene that encodes a protein
phosphatase [20]. Its deletion has been observed in high-grade
prostate cancer and is very important for prostate cancer
progression [21]. In this study, PTEN with a CMV promoter
was inserted into Ad.DD3.D55 to form Ad.DD3.D55-PTEN,
which has a prostate cancer replication specificity and antitumor
gene specificity. Ad.DD3.D55-PTEN efficaciously induces apop-
tosis in prostate cancer cells, eliminating prostate cancer
xenografts with higher antitumor efficiency.
Results
Prostate Cancer-Specific Transcriptional Activity of the
DD3 Promoter and cytopathic effect of Ad.DD3.D55
The minimal DD3 promoter activity in the absence of WPRE
was measured by luciferase-reporter expression, which showed the
minimal DD3 promoter typically exhibited much more activity in
the prostate cancer cell lines than in other cell lines. The pGL3-
control, which contains the SV40 promoter and enhancer, was
used as a positive control (activity=1000). As shown in Figure 1A,
expression driven by the DD3 promoter with WPRE was much
higher in LNCaP and 22RV1 than in other cells, including the
prostate cancer cell lines DU-145,PC3 and CL1. Although there
were differences in the levels of expression in these prostate cell
lines, these results indicate that WPRE could mediate enhance-
ment of gene expression and maintain the relatively restricted
activity of the DD3 promoter in prostate cell lines.
We constructed a new oncolytic virus, Ad.DD3-E1A.E1B(D55),
briefly Ad.DD3.D55 (Fig. 2A), which is a double-regulated
adenovirus in which the native promoter of E1A has been
replaced by the minimal DD3 promoter and the E1B-55K gene
has been deleted. The cytopathic effect of Ad.DD3.D55 was
evaluated in normal and tumor cells by crystal violet
staining(Fig. 1B). In prostate cancer cell lines 22RV1 and
DU145, the cytoxicity of Ad.DD3.D55 was comparable to the
single-regulated adenovirus Ad.DD3 and Ad.D55. In contrast, in
the non prostate cancer cell BEL-7404 and T24, the cytopathic
effect of Ad.DD3.D55 and Ad.DD3 was much lower, indicating
that the prostate cancer-specificity of cytoxicity exerted by
Ad.DD3.D55 was much more improved.
Then we measured expression levels of E1A in the different cells
infected with Ad.DD3.D55 (with WPRE) or Ad.DD3.D55(without
WPRE) (Fig. 1C), respectively. Expression of E1A was strongest in
the 22RV1 cells among all the cell lines tested, and did not change
significantly in the presence of WPRE. However, introduction of
WPRE indeed raised the expression levels of E1A in several
prostate cancer cell line including CL1, LNCaP, PC3 and DU-
145. Besides it, the data demonstrated that introduction of WPRE
did not significantly affect the restricted expression of E1A driven
by DD3 promoter in prostate cancer cells, providing a strong piece
of evidence supporting that WPRE is a promising candidate for
constructing an oncolytic adenovirus to target prostate cancer
cells.
Construction and Characterization of Ad.DD3.D55-PTEN
The PTEN expression cassette was introduced into the DD3
controlling double regulated-adenovirus Ad.DD3.D55 to generate
Ad.DD3.D55-PTEN (Fig. 2.A). The expression levels of PTEN
and E1A in different CTGVT viruses-infected cells were
determined by Western blotting after infecting the human prostate
cancer cell line CL1 (Fig. 2B). The replication-deficient adenovirus
Ad-PTEN with E1 region deletion and the double-regulated
adenovirus Ad.DD3.D55 were used as controls. As expected, the
double-regulated viruses Ad.DD3.D55 and Ad.DD3.D55-PTEN
expressed E1A protein at approximately the same levels as did
Ad.WT and failed to express the E1B-55K protein. Similar results
were obtained when protein expression was measured at the
mRNA level by real-time PCR (Fig. 2C). To characterize the
function of PTEN in Ad.DD3.D55-PTEN, the effects of its
expression on the phosphorylation status of Akt were examined by
Western blotting. As shown in Fig. 2D, infection by the oncolytic
virus led to an increase in phospho-Akt expression which was
detectable as early as 24 h after infection. Additionally, PTEN
expression inhibited phosphorylation of Akt at its activating
residue (Ser473) without diminishing total Akt protein levels
compared to the vector Ad.DD3.D55. These results are consistent
with PTEN’s lipid phosphatase activity. To further characterize
the viruses in vivo, levels of the viral protein hexon and the
therapeutic gene PTEN were measured in tumor specimens 7 days
after injection of the viruses. As shown in Figure 2E, high levels of
hexon were observed in the Ad.DD3.D55 and Ad.DD3.D55-
PTEN groups. The expression of the therapeutic gene PTEN was
also measured in these tumor specimens. The samples infected
with Ad-PTEN and Ad.DD3.D55-PTEN displayed high PTEN
expression levels, but PTEN expression was not observed in the
Ad.DD3.D55-treated group.
Prostate Cancer-Specific Cytotoxicity of Ad.DD3.D55-
PTEN In Vitro
The cytotoxicity of Ad.DD3.D55-PTEN was evaluated by
MTT assay in three prostate cancer cell lines CL1, LNCaP,
DU145, 22RV1, PC3 and two non-prostate cancer cell lines
T24(human urinary bladder carcinoma cell line) and BEL-
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of infected prostate cancer cells were much inhibited with different
degree, while the highest efficiency of inhibition by Ad.DD3.D55-
PTEN was observed in LNCaP cells and CL1 cells (Fig. 3A).
These data also showed that cytotoxicity of Ad.DD3.D55-PTEN is
significantly higher than that of Ad.DD3.D55. However, both of
virus were shown to be unable to inhibit growth of non-prostate
cancer cells significantly (Fig. 3A).
The cytotoxicity of Ad.DD3.D55-PTEN was also analyzed by
staining with crystal violet as shown in Figure 3B. Ad.DD3.D55-
PTEN had a strong cytotoxic effect on the prostate cancer cells.
LNCaP cells and CL1 cells were more sensitive to the cytotoxicity
exerted by Ad.DD3.D55-PTEN than were DU-145 and 22RV1
cells. However, little or no cytotoxicity was observed in non-
prostate cancer cell lines, such as T-24, BEL-7404, and normal cell
lines, HFL-I and BEAS-2B. These results indicate that the
cytotoxicity of Ad.DD3.D55-PTEN was not only much stronger
than that of Ad.DD3.D55 due to the expression of PTEN, but was
also highly restricted to prostate cancer cells.
Ad.DD3.D55-PTEN Induces Apoptosis in Prostate Cancer
Cells In Vitro
We stained cells with Hoechst33258 to further analyze the
apoptosis-inducing capacity of Ad.DD3.D55-PTEN in vitro.A s
shown in Figure 4A, Ad.DD3.D55-PTEN induced significant
apoptosis in CL1 and 22RV1 cells. However, replication-
incompetent Ad-PTEN and double-regulated Ad.DD3.D55 ex-
hibited a marginal ability to induce apoptosis. The flow cytometry
Figure 1. Prostate cancer-specific expression driven by the DD3 promoter in the presence of WPRE. A. The luciferase activity of the DD3
promoter in the presence of WPRE is expressed compared to the pGL3-control (activity=1000). Cells were seeded in 24-well plates. Forty-eight hours
after infection with the reporter plasmids pGL3-control or pGL3-DD3-WPRE, the cells were harvested, and the luciferase activity was measured. The
activity of pGL3-DD3-WPRE relative to the pGL3-control is presented as the mean 6 standard deviation (SD) of three transfections. B. The expression
of E1A by Ad.DD3.D55 (without WPRE) and Ad.DD3.D55 in different cell lines was evaluated. a-Tubulin was evaluated as a loading control. C. Crystal
violet assay. Cells on 24-well plates were infected with different viruses at the indicated MOIs. Cytotoxicity was observed by crystal violet staining at
five days after infection.
doi:10.1371/journal.pone.0035153.g001
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fraction of cells in the sub-G1 phase. Infection with Ad.DD3.D55-
PTEN increased the number of cells in the sub-G1 phase in the
tested prostate cell lines(CL1, DU145, 22RV1, PC3) and a higher
apoptotic index was found in 22RV1 cells (43.135%) than in
DU145, PC3 or CL1 cells, consistent with the higher expression of
E1A in the 22RV1 cell line(Fig. 4B).
Ad.DD3.D55-PTEN Induces Apoptosis through Intrinsic
and Extrinsic Signaling Pathways
The mechanism of Ad.DD3.D55-PTEN-induced apoptosis was
studied. As shown in Figure 5B, the pan-caspase inhibitor Z-VAD-
fmk inhibited the cell death induced by Ad.DD3.D55-PTEN in
CL1 cells. This result indicates that the cell death induced by
Ad.DD3.D55-PTEN is caspase-dependent. Additionally, a series
Figure 2. Characterization of Ad.DD3.D55-PTEN. A. Schematic diagram of Ad.DD3.D55-PTEN. The endogenous promoter of E1A was replaced
by the DD3 promoter, and the E1B-55K gene was deleted. The PTEN expression cassette was inserted into Ad.DD3.D55 to construct Ad.DD3.D55-
PTEN. ITR, inverted terminal repeat. B. Characterization of Ad-PTEN, Ad.DD3.D55 and Ad.DD3.D55-PTEN expression by Western blot analysis. The
expression of PTEN, E1A and E1B-55K by Ad-PTEN, Ad.DD3.D55 or Ad.DD3.D55-PTEN in CL1 cells was evaluated. Ad.WT was used as a positive control.
a-Tubulin was evaluated as a loading control. C. Relative mRNA levels of PTEN and E1A in 22RV1 cells infected with Ad-PTEN, Ad.DD3.D55 and
Ad.DD3.D55-PTEN. GAPDH was evaluated as an internal reference. The data are presented as the mean 6 SD of three separate experiments. D.
Western blot analysis of the total and phosphorylated Akt protein levels in CL1 cells infected with Ad.DD3.D55 and Ad.DD3.D55-PTEN. E. Analysis of
tumor sections derived from tumors treated with PBS or one of various adenoviruses by hematoxylin and eosin staining and hexon and PTEN
immunostaining. Scale bar, 100 mm.
doi:10.1371/journal.pone.0035153.g002
Figure 3. Prostate cancer-specific cytotoxicity of Ad.DD3.D55-PTEN. A. MTT assay. The six cell lines indicated above were seeded on 96-well
plates and infected with different viruses at an MOI of 10. Cell viability was measured by MTT assays at 0, 24, 48, 72, 96 and 120 hours post-infection.
The results are presented as the mean 6 SD of five separate experiments and are expressed as the percentage relative to mock-treated control cells.
B. Crystal violet assay. Cells on 24-well plates were infected with different viruses at the indicated MOIs. Cytotoxicity was observed by crystal violet
staining at five days after infection.
doi:10.1371/journal.pone.0035153.g003
Oncolytic Virus Specific for Prostate Cancer
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35153of caspase-dependent apoptosis signaling cascades were analyzed
by Western blotting (Fig. 5A). Enhanced PARP cleavage and
activation of procaspase-3, procaspase-8 were detected in
Ad.DD3.D55-PTEN-infected cells (Fig. 5A). We also detected a
time-dependent reduction in level of precaspase-9 in
Ad.DD3.D55-PTEN-infected cells (Fig. 5A), consistent with the
activation of the mitochondria-mediated apoptosis signaling
pathway. The integrity of the cell mitochondria was evaluated
with the potentiometric fluorescent dye JC-1(Fig. 5B). Flow
cytometry revealed that infection with Ad.DD3.D55-PTEN
resulted in a significant decrease in mitochondrial transmembrane
electrical potential (Fig. 5C). Taken together, these observations
indicate that PTEN effectively enhanced Ad.DD3.D55-induced
apoptosis by intrinsic and extrinsic pathways.
Suppression of Tumor Growth by Ad.DD3.D55-PTEN
Induces Apoptosis In Vivo
The results presented above show that the anti-tumor effect of
the CTGVT agent Ad.DD3.D55-PTEN is much better than
either the oncolytic virus Ad.DD3.D55 or Ad.PTEN alone. Of the
prostate cancer cell lines tested, Ad.DD3.D55-PTEN killed
LNCaP and CL-1 cells with the highest efficiency. We selected
the cell line CL1, an androgen-independent subclone of LNCaP,
to evaluate the oncolytic potential of Ad.DD3.D55-PTEN because
Figure 4. Ad.DD3.D55-PTEN induces apoptosis of prostate cancer cells. A. CL1 and 22RV1 cells were stained with Hoechst 33258 at 48 hours
after viral infection. The arrows indicate the apoptotic cells. Scale bar, 10 mm. B. Flow cytometric analysis of propidium iodide-stained cells was
performed at 48 hours after infection. The percentages of sub-G1 cells are shown. The results are presented as the mean 6 SD of three separate
experiments (** indicates P,0.01; * indicates P,0.05; N/S indicates P.0.05).
doi:10.1371/journal.pone.0035153.g004
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in Figure 6A, the tumor growth after injection of was almost
completedly inhibited with the final tumor volume after
Ad.DD3.D55-PTEN treatment less than the initial volume at
the beginning of Ad.DD3.D55-PTEN treatment. Another way of
saying, not only did Ad.DD3.D55-PTEN-infected tumors not
grow, but their volumes actually shrunk by 41.3% when measured
20 days after the injection. This shows the powerful effect of
Ad.DD3.D55-PTEN on tumor growth. However, both
Ad.DD3.D55 and Ad.PTEN inhibited tumor growth with a much
lower efficiency, compared to that of Ad.DD3.D55-PTEN.
The viral kinetics study in vivo further illustrate the superiority of
Ad.DD3.D55-PTEN with its viral DNA quantity up to 100 times
greater than that of Ad-PTEN within 72 h and lasting for 2 weeks
(Fig. 6B). TUNEL analysis revealed that injection of
Ad.DD3.D55-PTEN caused significant amount of apoptosis in
Figure 5. Ad.DD3.D55-PTEN activates caspase-mediated apoptosis signaling pathways. A. Western blot analysis of apoptosis-related
proteinsinCL1cellsinfectedwithAd.DD3.D55orAd.DD3.D55-PTEN.B.CL1cellsweretreatedwiththeindicatedagentsandcellviabilitywasanalyzedby
the MTT assay after 120 hours. For the Z-VAD-fmk inhibition assay, cells were pre-treated with Z-VAD-fmk (20 mM) 2 h before virus infection. The results
are presented as the mean 6 SD of three separate experiments (** indicates P,0.01; * indicates P,0.05; N/S indicates P.0.05). C. Analysis of the
mitochondrial membrane potential of CL1 cells by FACS after JC-1 staining. The percentage of cells in the trapeziform region is shown.
doi:10.1371/journal.pone.0035153.g005
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tumors, and little in Ad-PTEN-treated tumors(Fig. 6C).
Discussion
In this study, Ad.DD3.D55-PTEN demonstrated an excellent
antitumor effect in vitro and in vivo. Two major factors contribute to
the cytotoxicity exerted by Ad.DD3.D55-PTEN. The first is that it
replicates selectively in prostate cancer cells. We previously
reported that the minimal DD3 promoter-controlled oncolytic
virus replicated selectively in prostate cancer cells [17], although
the promoter activity was not very satisfactory. PSA is a well-
known biomarker of prostate cancer and its promoter has been
widely used to study biotherapies for prostate cancer, including
gene therapy with different vectors [22,23,24,25]. Different
recombinant promoters have been generated based on the
Prostate Cancer-specific activity of a promoter or enhancer to
increase the Prostate Cancer-specific activity of the promoter
controlling the replication of the oncolytic virus [26,27,28,29]. Cell
killing efficacy could be improved by many methods, such as
combining the oncolytic adenovirus with radiotherapy or
chemotherapy. Clinical trials have shown that the combination
of ONYX-15 virus and chemotherapy elicits a stronger anti-tumor
response against head and neck cancer than ONYX-15 or
chemotherapy alone [30]. Patients with prostate cancer have
been treated most frequently with androgen ablation. Because the
activity of the PSA promoter/enhancer is highly dependent on
endogenous androgen [31], the in vivo cytotoxicity of a PSA
promoter/enhancer-based oncolytic virus could be reduced
significantly if it was used in patients who have been treated with
androgen ablation. In this study, we introduced WPRE in the
DD3-controlled E1A expression cassette. Interestingly, the pres-
ence of WPRE raised the levels of reporter expression considerably
but did not significantly affect the restricted expression in prostate
cancer cells. To our knowledge, this is the first reported use of
WPRE in the generation of an oncolytic virus. In addition, our
data show that Ad.DD3.D55-PTEN, in which E1A expression is
under the control of the DD3 promoter and WPRE, exerted a
strong inhibitory effect on the growth of androgen-dependent as
well as androgen-independent cell lines, including CL1, DU145
and 22RV1 in cell culture and CL1 tumor growth in a xenograft
nude mouse. Ad.DD3.D55-PTEN has a powerful cytotoxic effect
in androgen-independent cell lines. Therefore, E1A expression
under the control of the DD3 promoter and WPRE may be
clinically significant for oncolytic viral therapy of patients with
prostate cancer.
Our results showed that the expression of PTEN played the
second key role in the cytotoxicity of Ad.DD3.D55-PTEN. PTEN
acts as a phosphatidylinositol phosphatase with a possible role in
phosphatidylinositol 39-kinase (PI39K)-mediated signal transduc-
tion, suppressing the PI3K/AKT pathway by reducing the level of
PI39K in the cell [32,33]. The oncolytic virus Ad.DD3.D55 and
Ad.DD3.D55-PTEN led to an increase in phospho-Akt expression
at 24 h after infection(Fig. 2.D); the activation of PI3K-Akt
signaling is the pathway employed by viruses for viral endocytosis
and replication [34,35,36,37]. Ad.DD3.D55-PTEN inhibited
phosphorylation of Akt at its activating residue (Ser473) as a
result of PTEN expression, while the activation of Akt was
maintained with the infection of Ad.DD3.D55(Fig. 2.D). The
difference clearly indicated the powerful role of PTEN. In
addition, PTEN has been identified as the inactivating alteration
Figure 6. Ad.DD3.D55-PTEN inhibits the growth of prostate cancer cell xenograft tumors. A. Antitumor effect of infection of CL1
xenograft tumors with different adenoviruses. The tumor volume was measured and is presented as the mean 6 SD. B. Ad.DD3.D55-PTEN inhibits the
growth of CL1 xenograft tumors. Analysis of the viral kinetics of Ad-PTEN or Ad.DD3.D55-PTEN-treated 22RV1 tumors by real-time PCR. Adenovirus E3
region was amplified to evaluate the viral DNA content. b-actin DNA was used as an internal control. (NS means P.0.05, no statistical significance). C.
Analysis of tumor sections derived from tumors treated with PBS or one of various adenoviruses by TUNEL staining. Scale bar, 100 mm.
doi:10.1371/journal.pone.0035153.g006
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prostate, bladder, melanoma and kidney tumors, astrocytoma, and
leukemia [38]. In prostate cancer, the loss of the PTEN protein is
correlated with tumors of high grade and stage, suggesting that
alterations in the PTEN gene may be associated with prostate
cancer progression [21,39]. Wu et al. established a mouse model
with prostate-specific deletion of PTEN [40]. This mouse model
recapitulates prostate cancer progression in humans: initiation of
prostate cancer with prostatic intraepithelial neoplasia, followed by
progression to invasive adenocarcinoma and subsequent metasta-
sis. Therefore, PTEN is an optimal candidate for cancer gene
therapy due to its unique properties. Introduction of PTEN by
adenovirus or retrovirus has been studied for bio-therapy of
various type of cancer, including ovarian, endometrial, bladder,
gastric, colorectal, and esophageal cancers and glioblastoma
[41,42,43,44,45,46,47]. For example, Gallick et al. reported that
the adenoviral-mediated expression of PTEN inhibited prolifera-
tion and metastasis of human prostate cancer cells in vitro and in
vivo [48]. Adenoviral-mediated PTEN transgene expression
combined with radiotherapy, chemotherapy and other cancer-
suppressing genes has been used to treat prostate cancer cells to
boost the antitumor effect [49,50,51,52]. In this study, high levels
of PTEN expression driven by the CMV promoter were mediated
by an oncolytic virus that replicated selectively in prostate cancer
cells by using DD3 promoter to drive E1A expression. The
antitumor efficacy of PTEN in the oncolytic virus was much
enhanced compared with the adenovirus-mediated PTEN that
was previously reported for use in prostate cancer [48,52], it could
be resulted from that Ad.DD3.D55-PTEN induced a massive
apoptosis in prostate cancer cells by intrinsic and extrinsic
pathways.
We observed varying sensitivities of the different prostate cancer
cell lines to the cytotoxicity of Ad.DD3.D55-PTEN. The level of
reporter expression driven by the DD3 promoter and WPRE in
LNCaP cells was only 21.79% of that in 22RV1 cells (Fig. 1),
suggesting a lower replication of Ad.DD3.D55-PTEN in LNCaP
cells, which would seem inconsistent with the higher killing efficacy
of Ad.DD3.D55-PTEN in LNCaP cells than in 22RV1 cells
(Fig. 3). However, 22RV1 cells express a functional PTEN, while
LNCaP cells do not [53]. Given the above data, Ad.DD3.D55-
PTEN probably exerts a stronger cytotoxic effect in PTEN-
negative PCa cells than in PTEN-positive PCa cells.
Volumes of tumor of CL1 cells was redued by 41.3% 20 days
after infected with Ad.DD3.D55-PTEN in the nude mouse
(Fig. 6A) strongly suggests that Ad.DD3.D55-PTEN has the
therapeutic potential for the treatment of androgen-independent
cancers. This study revealed that adenoviral replication slowed
after approximately 12 days of active replication (Fig. 6B).
Interestingly, even the rate of oncolytic virus kept very low in
vivo after the period (Fig. 6B), the infected tumor still did not
significantly grow(Fig. 6A). Its mechanism for this phenomenon
remains unknown. One plausible explanation is that a vast
majority of cancer cells was killed in the first days after injection of
Ad.DD3.D55-PTEN, while growth of the remaining cancer cells is
efficiently inhibited even in the presence of a minimal amount of
oncolytic virus. The phenomenon is probably encouraging since
most of virus will be cleared up in vivo when the oncolytic virus are
used clinically.
In conclusion, we developed a novel prostate-specific
CTGVT(CTGVT-PCa), Ad.DD3.D55-PTEN, by controlling the
expression of the E1A gene with a minimal DD3 promoter and
WPRE. Ad.DD3.D55-PTEN had excellent anti-tumor efficacy in
both androgen-dependent and -independent prostate cancer cell
lines. This report also provides a new strategy for constructing a
CTGVT-PCa with tumor types specificity that have few tumor-
specific promoters available.
Materials and Methods
Ethics Statement and Animal Experiment
Male BALB/c nude mice (4-week-old) were maintained and
used in a light and temperature controlled room in an AAALAC-
accredited facility, and given water and lab chow ad libitum [17].
All experimental procedures were approved by the Institutional
Animal Care and Use Committee of Shanghai Institute of
Biochemistry and Cell Biology under protocol IBCB-SPF0029.
To establish xenograft tumors, 5610
6 22RV1 or CL1 cells in
150 ml DMEM were subcutaneously injected into the right flank of
each mouse. When tumors reached 70–150 mm
3 in size, mice
were randomly assigned to one of four groups (six mice per group).
Adenovirus (2610
9 PFUs per mouse) or PBS was injected into the
tumors every other day, with a total of three injections. The tumor
volume (mm
3) was measured with a vernier caliper every four days
and calculated as (length6width
2)/2. To study viral kinetics in vivo,
tumors injected with Ad-PTEN or Ad.DD3.D55-PTEN were
collected at 3, 6, 9, 12 and 15 days after the last injection and
quickly frozen in liquid nitrogen. The total tumor DNA was
extracted using the Genomic DNA MiniPreps Kit (Generay
Biotech, Shanghai, China). Viral DNA was measured by real-time
PCR using primers that anneal to the adenovirus E3 region. The
oligonucleotide primers used for amplification are listed in Table 1.
Genomic DNA amplified by b-actin primers was used as an
internal control.
Cells and Cell Culture
The human cell lines used in this study were LNCaP, DU145,
22RV1,PC3 (prostate cancer), T-24 (bladder cancer), BEL-7404
(liver cancer), HeLa (cervical cancer), BEAS-2B (bronchial
epithelial cell), HFL-I (embryonic lung fibroblast), L-02 (liver cell)
and WISH (amnion cell). All cell lines were purchased from the
Cell Bank of the Type Culture Collection of the Chinese Academy
of Sciences (Shanghai, China). CL1 cells (prostate cancer) were
grown as described by Tso et al. [54]. HEK293 was obtained from
Microbix Biosystems, Inc. (Toronto, Ontario, Canada). The cell
lines were incubated in DMEM or RPMI 1640 supplemented with
5–10% heat-inactivated fetal bovine serum (FBS) at 37uCi na
humidified air atmosphere with 5% CO2.
Table 1. Nucleotide sequence of oligonucleotide primers
used for virus identification, RT-PCR and real-time PCR.
Gene Direction Nucleotide sequence
adenovirus E1A forward 59-gaggagtttgtgttagattagattatgtg-39
reverse 59-cagatgagccacataataataagg-39
GAPDH forward 59-ggtgaaggtcggagtcaacgga-39
reverse 59-gagggatctcgctcctggaaga-39
PTEN forward 59-gacgaactggtgtaatgata-39
reverse 59-gtgccactggtctataatcc-39
adenovirus E3 forward 59-aacagagatgaccaacacaac-39
reverse 59-gtgccactggtctataatcc-39
b-actin forward 59-tcacccacactgtgcccatctacga-39
reverse 59-cagcggaaccgctcattgccaatgg-39
doi:10.1371/journal.pone.0035153.t001
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Adenoviruses
The minimal DD3 promoter (AF279290 nt309–522) was cloned
as described previously [17]. The luciferase reporter plasmids
pGL3-basic and pGL3-control were purchased from Promega
Corp. (Madison, WI, USA). The woodchuck hepatitis virus post-
transcriptional regulatory element (WPRE) was a kind gift from
Dr. Xiaoming Xie and was inserted downstream of the luciferase
reporter gene between the XbaI and NheI sites in the plasmid
pGL3-DD3 to construct the plasmid pGL3-DD3-WPRE. The
luciferase reporter gene assay was performed as previously
described [17]. All results were the average of three independent
experiments.
Different adenoviruses were generated by homologous recom-
bination using Effectene Transfection Reagent (Qiagen, Germany)
with the plasmid pBHGE3 and the plasmids pAd.DD3.D55 or
pAd.DD3.D55-PTEN. Wild-type adenovirus (Ad.WT) was previ-
ously preserved in our laboratory [55]. The viral structure was
confirmed by PCR. The sequences of the primers used for PCR
are listed in Table 1.
Western Blot Analysis
The different cells were harvested at various times after
infection with the indicated viruses at an MOI of 10. The total
protein was extracted in cell lysis buffer (Beyotime, Shanghai,
China). Protein concentrations were measured with the Enhanced
BCA Protein Assay Kit (Beyotime, Shanghai, China). The protein
samples were electrophoretically separated on an 8–12% SDS-
polyacrylamide gel and transferred to a PVDF membrane. The
membranes were blocked for 30 min with 5% nonfat milk,
sequentially incubated with primary and secondary antibodies and
finally developed with ECL Western blot detection reagents
(Pierce Biotechnology, Rockford, Illinois, USA) according to the
manufacturer’s instructions. Primary antibodies for E1A, E1B-
55K, procaspase-3, poly(ADP-ribose) polymerase (PARP), Akt(-
Pan)(C67E7) and phospho-Akt(Ser473)(D9E) and all of the
secondary antibodies were obtained from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA, USA). PTEN, cleaved-PARP and
procaspase-8 antibodies were purchased from Cell Signaling Inc.
(Danvers, MA, USA). The procaspase-9 antibody was purchased
from Thermo Fisher Scientific Inc. (Fremont, CA, USA). The
XIAP antibody was purchased from R&D Systems Inc. (Minne-
apolis, MN, USA) and the tubulin antibody was manufactured by
Sigma-Aldrich (St. Louis, MO).
Crystal Violet Cytopathic Assay
Cells were seeded in 24-well plates and infected with Ad-PTEN,
Ad.DD3.D55, Ad.DD3.D55-PTEN or wild type adenovirus at
various MOIs. Five days after infection, cells were exposed to 2%
crystal violet dissolved in 20% methanol for 5 min. The plates
were then washed with distilled water (dH2O) and documented by
photography.
Colorimetric MTT (Tetrazolium) Cell Viability Assay
Cells cultured in 96-well plates were incubated with viruses at
an MOI of 10. MTT solution (20 ml, 5 mg/ml) was added to each
well after various times and the absorbance was measured in dual
wavelength mode (595 nm and 655 nm). The percentage of cell
viability was calculated as follows: (mean A595/A655 of infected
cells)/(mean A595/A655 of uninfected cells)6100.
Apoptotic Cell Staining
Cells grown on glass coverslips were treated with viruses at an
MOI of 10 for 48 h and stained with 1 mg/ml Hoechst 33258
(Molecular Probes, Eugene, OR, USA).
Immunohistochemical Analysis and TdT–mediated dUTP
Nick End Labeling (TUNEL) Assay
Frozen tumor sections were incubated in 1% H2O2 and 0.4%
Triton X-100 to eliminate endogenous peroxidase activity. The
sections were then blocked with the blocking serum and incubated
with the corresponding antibody. The subsequent procedures were
performed using the ABC Staining System (Westang, Shanghai,
China) according to the manufacturer’s instructions.
The apoptotic cells in tumor tissue sections were observed by
using terminal deoxynucleotidyl transferase-mediated dUTP-
biotin nick end labeling staining with a TACSTM 2 TdT-DAB
In Situ Apoptosis Detection Kit (Trevigen, Gaithersburg, MD,
USA) according to the manufacturer’s instructions. The sections
were counterstained with hematoxylin. All sections were visualized
with an Olympus BX51 microscope (Olympus, Tokyo, Japan).
Statistical Analysis
The differences between the groups were assessed using the
Student’s t-test.
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